The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
Mother-to-child transmission (MTCT) is the most common mode of perpetuating chronic hepatitis
B virus (HBV) infection in endemic countries. Many studies have demonstrated antepartum
anti-viral therapy (AVT) is a advisable option to reduce mother-to-child transmission and the
risk of vaccination breakthrough in infants who received passive-active immunoprophylaxis.
However, several controversies over antiviral treatment have not been resolved, that is,
optimal duration, effect of postpartum therapy, and risk of postpartum alanine
aminotransferase (ALT) flare after withdrawal. Will the risk of postpartum hepatitis flares
increase after short-term AVT in late pregnancy for maternal HBV infection is discontinued?
Is there any correlation between postpartum hepatitis flares and withdrawal time? Will the
proportion of postpartum flares be reduced if extending the duration of AVT after delivery?
There is an urgent need in this area. This study mainly investigated the safety of antiviral
therapy in preventing HBV mother-to-child transmission in pregnant women after
discontinuation.